Velneperit

Velneperit
Clinical data
ATC code	None;
Identifiers
	IUPAC name trans-4-(tert-butylsulfonylamino)-N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1-carboxamide;
CAS Number	342577-38-2;
PubChem CID	20629114;
ChemSpider	25948511;
CompTox Dashboard (EPA)	DTXSID20955806 ;
Chemical and physical data
Formula	C17H24F3N3O3S
Molar mass	407.451 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)S(=O)(=O)NC2CCC(CC2)C(=O)Nc1ncc(C(F)(F)F)cc1;
	InChI InChI=1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)/t11-,13-; Key:WGEWUYACXPEFPO-AULYBMBSSA-N;

Velneperit (S-2367) is a drug developed by Shionogi, which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y₅. It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. However it was still considered a successful proof of concept of the potential of Y₅ receptor antagonists as possible anti-obesity agents in future.^[1]^[2]^[3]

References

^ Yukioka H. A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent. (Japanese). Nihon Yakurigaku Zasshi. 2010 Nov;136(5):270-4. PMID 21079365
^ Oda S, et al. Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist. Org. Process Res. Dev. 2015; 19(4):531–536. doi: 10.1021/acs.oprd.5b00023
^ George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017 PMID 24064009

Template:Neuropeptide agonists and antagonists

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Yukioka H. A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent. (Japanese). Nihon Yakurigaku Zasshi. 2010 Nov;136(5):270-4. PMID 21079365

[2] Oda S, et al. Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist. Org. Process Res. Dev. 2015; 19(4):531–536. doi: 10.1021/acs.oprd.5b00023

[3] George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017 PMID 24064009

[1]

[2]

[3]